Home/Filings/4/0001127602-21-009099
4//SEC Filing

Perry Nicole D 4

Accession 0001127602-21-009099

CIK 0001492422other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 4:05 PM ET

Size

8.1 KB

Accession

0001127602-21-009099

Insider Transaction Report

Form 4
Period: 2021-03-01
Perry Nicole D
Vice President - Finance
Transactions
  • Exercise/Conversion

    Common Stock

    2021-03-01$3.76/sh+2,000$7,5204,347 total
  • Sale

    Common Stock

    2021-03-01$50.00/sh2,000$100,0002,347 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-03-012,00011,161 total
    Exercise: $3.76Exp: 2025-07-31Common Stock (2,000 underlying)
Footnotes (2)
  • [F1]This is a scheduled exercise from a 10B5-1 trading plan.
  • [F2]This option was granted on July 31, 2015 and is fully vested.

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1
  • filerCIK 0001657874

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 4:05 PM ET
Size
8.1 KB